• 6 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    An overview of immune checkpoint inhibitors in breast cancer
    Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-nega [...] Read more.
    Federica Miglietta ... Nicla La Verde
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:452–472
    DOI: https://doi.org/10.37349/etat.2020.00029
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:3536
    Download:111
    Open Access
    Review
    Circulating biomarkers in malignant pleural mesothelioma
    Malignant pleural mesothelioma (MPM) is an aggressive tumor strictly connected to asbestos exposure. Prognosis is dismal as diagnosis commonly occurs in advanced stage. Radiological screenings have  [...] Read more.
    Giuseppe Viscardi ... Giulia Galli
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:434–451
    DOI: https://doi.org/10.37349/etat.2020.00028
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:2878
    Download:67
    Open Access
    Letter to the Editor
    Is hyperprogressive disease a specific phenomenom of immunotherapy?
    Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particula [...] Read more.
    Marta Brambilla ... Mario Occhipinti
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:427–433
    DOI: https://doi.org/10.37349/etat.2020.00027
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:2101
    Download:29
    Open Access
    Review
    An overview of the potential anticancer properties of cardamonin
    Cancer is one of the leading causes of mortality, contributing to 9.6 million deaths globally in 2018 alone. Although several cancer treatments exist, they are often associated with severe side effe [...] Read more.
    Shanaya Ramchandani ... Manoj Garg
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:413–426
    DOI: https://doi.org/10.37349/etat.2020.00026
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:3655
    Download:60
    Open Access
    Review
    Targeting transcription factors in cancer drug discovery
    Cancer drug discovery is currently dominated by clinical trials or clinical research. Several potential drug candidates have been brought into the pipeline of drug discovery after showing very promi [...] Read more.
    Partha Mitra
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:401–412
    DOI: https://doi.org/10.37349/etat.2020.00025
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:4241
    Download:205
    Open Access
    Review
    Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
    Liquid biopsy has emerged as a minimally invasive alternative to tumor tissue analysis for the management of lung cancer patients, especially for epidermal growth factor receptor (EGFR) oncogene add [...] Read more.
    Marialucia Iacovino ... Francesca Sparano
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:391–400
    DOI: https://doi.org/10.37349/etat.2020.00024
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:2433
    Download:62